In the HIV franchise, GSK's ViiV Healthcare joint venture, in which GSK holds a 71.5 percent equity interest, faces direct competition from Merck's islatravir and Gilead Sciences' lenacapavir, the latter of which demonstrated a 98.5 percent virologic suppression rate in the CAPELLA trial for multi-drug resistant HIV, threatening to displace Dovato and Cabenuva as the standard of care for treatment-experienced patients. The simultaneous pressure on both the vaccine and HIV franchises creates a dual revenue cliff scenario that threatens to reduce total corporate revenue by 15 percent between 2025 and 2028, a structural deficit that the current R&D pipeline, heavily weighted toward early-stage oncology assets with binary clinical outcomes, is not positioned to fill in the near term. These compounding challenges — regulatory volatility in vaccines, patent cliffs in HIV, competitive erosion in respiratory, and pricing pressure in China — create a perfect storm that threatens to compress the company's operating margin from its current 24.5 percent to below 20 percent by 2027 if management cannot accelerate the commercialization of its late-stage pipeline assets and successfully navigate the complex reimbursement landscape in its key global markets. However, this optimistic outlook is contingent on the successful navigation of the complex regulatory and reimbursement landscapes in the US and Europe, where the Inflation Reduction Act and the European Health Technology Assessment regulation threaten to compress the pricing power of new launches, and on the ability of the clinical teams to execute the Phase 3 trials without the delays that have plagued the company's oncology portfolio in the past.
Despite these initial challenges, the merger ultimately created a diversified pharmaceutical powerhouse that was able to weather the patent cliffs of the early 2000s and establish a strong presence in the emerging markets of China and India, setting the stage for the company's subsequent evolution into the modern GlaxoSmithKline.